Histology predicts a favorable outcome in young children with desmoplastic medulloblastoma: a report from the children's oncology group.
BACKGROUND
Contemporary therapy for medulloblastoma results in adverse neurocognitive effects on young children, particularly those under the age of 3. Stratification of patients by risk group may allow toxic treatment to be avoided.


METHODS
Seventy-six patients diagnosed with medulloblastoma and enrolled on CCG-9921 underwent central review of pathology, and histologic subtype was designated as desmoplastic or nondesmoplastic. Nonparametric event-free survival (EFS) and survival (OS) curves were computed using the product limit (Kaplan-Meier) estimates, and the log-rank test was used to compare survival according to histologic subtype.


RESULTS
Patients with desmoplastic medulloblastoma experienced a favorable EFS of 77% ± 9% and OS of 85% ± 8% compared with EFS of 17% ± 5% and OS of 29% ± 6% for patients with tumors in the nondesmoplastic group (P < .0001 for both EFS and OS comparisons). Patients without disease progression did not receive radiation therapy.


CONCLUSIONS
Children less than 3 with desmoplastic histology of medulloblastoma represent a lower-risk group for whom reduction of therapy, including elimination of radiation therapy, is an appropriate strategy.
Division of Hematology/Oncology, Seattle Children's, Seattle, Washington, USA. sarah.leary@seattlechildrens.org
Sarah E S
SE
Leary
Tianni
T
Zhou
Emiko
E
Holmes
J Russel
JR
Geyer
Douglas C
DC
Miller
D002528:Cerebellar Neoplasms / Q000473:pathology* / Q000628:therapy; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000473:pathology* / Q000628:therapy; D009362:Neoplasm Metastasis; D011379:Prognosis
Pediatr Blood Cancer. 2010 Apr;54(4):635-7
20146217
Bone Marrow Transplant. 2005 Mar;35 Suppl 1:S31-4
15812527
J Pediatr Psychol. 2007 Oct;32(9):1040-9
17329318
Cancer. 2002 Jan 15;94(2):552-60
11900240
Lancet Oncol. 2006 Oct;7(10):813-20
17012043
J Neurosurg. 1990 Apr;72(4):572-82
2319316
Lancet Oncol. 2005 Aug;6(8):573-80
16054568
Curr Treat Options Neurol. 2006 Jul;8(4):319-34
16942675
Pediatr Blood Cancer. 2007 Mar;48(3):278-84
16456857
J Clin Oncol. 2005 Oct 1;23(28):7152-60
16192599
J Clin Oncol. 2005 Oct 20;23(30):7621-31
16234523
Pediatr Blood Cancer. 2010 Mar;54(3):369-76
19908297
Acta Neuropathol. 2007 Aug;114(2):97-109
17618441
J Clin Oncol. 2006 Apr 20;24(12):1924-31
16567768
Neuro Oncol. 2009 Apr;11(2):201-10
18818397
J Clin Oncol. 1994 Jun;12(6):1212-6
8201384
J Clin Oncol. 2010 Nov 20;28(33):4961-8
20940197
Pediatr Blood Cancer. 2008 Jun;50(6):1169-75
18293379
Eur J Cancer. 2010 Jan;46(1):120-33
19818598
N Engl J Med. 2005 Mar 10;352(10):978-86
15758008
Lancet Oncol. 2004 Jul;5(7):399-408
15231246
J Clin Oncol. 2004 Mar 15;22(6):984-93
14970185
J Clin Oncol. 2006 Sep 1;24(25):4202-8
16943538
J Neuropathol Exp Neurol. 2004 May;63(5):441-9
15198123